Irvine-based Alteryx Inc. reported fourth quarter revenue and operating income that topped Wall Street expectations, with shares trading 17% higher after the release of the results.
Nemus Bioscience Inc. (OTCQB: NMUS) received a $1.75 million private placement from majority shareholder Emerald Health Sciences Inc. and other investors.
Luxury goods distributor MadaLuxe Group in Seal Beach promoted Adam Freede from president to chief executive.
Tustin-based Avid Bioservices Inc. yesterday priced a public offering of 9 million shares of common stock at $2.25 apiece, and expects more than $20 million in gross proceeds after the offering closes next week.
For the second time in a year, the fate of Jim Mazzo is in the hands of a federal jury. Prosecutors are again alleging that the founder and former chief executive of Advanced Medical Optics (AMO) violated insider trading laws when he disclosed to his friend and Laguna Beach neighbor Doug DeCinces that his company was being bought by Abbott Laboratories.
Avid Bioservices Inc. in Tustin will sell its clinical-stage immunotherapy cancer drug candidate to Oncologie Inc. for $8 million upfront—with payments spread over six months—and up to $95 million in development, regulatory and commercialization milestones.
The board of Qualcomm Inc. today unanimously rejected Broadcom Ltd.’s latest unsolicited cash and stock bid of $121 billion, or $82.00 per share.
Lake Forest-based ReVision Optics Inc. has shut down saying, “it is with regret, that we have to close our doors.”
Irvine-based Evolus Inc. priced its initial public offering of five million shares of common stock at $12 per share, the low end of an earlier-announced $12 to $14 range.
Shares of TTM Technologies Inc. declined about 3% to a $1.5 billion market cap after the Costa Mesa-based company provided an outlook on adjusted profits this quarter that were below Wall Street expectations.
Leadership changes were announced on Tuesday for Huntington Beach-based Boardriders Inc. following the recent tragedy involving Chief Executive Pierre Agnes.
Allergan PLC reported strong fourth-quarter revenue of $4.3 billion, up 12% from a year earlier, and full-year revenue of nearly $16 billion, a 9.4% increase.
Broadcom Ltd. raised its hostile bid for San Diego rival Qualcomm Inc. this morning to $121 billion, or $82.00 per share.
Edwards Lifesciences Corp. finished the year strong, reporting $889 million in fourth-quarter sales, up 16% from a year earlier.